Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 10:50AM ET
44.04
Dollar change
-0.67
Percentage change
-1.49
%
IndexRUT P/E- EPS (ttm)-3.77 Insider Own6.72% Shs Outstand78.86M Perf Week-1.73%
Market Cap3.47B Forward P/E- EPS next Y-3.79 Insider Trans-6.14% Shs Float73.56M Perf Month-14.31%
Income-235.46M PEG- EPS next Q-0.86 Inst Own98.60% Short Float6.83% Perf Quarter-2.52%
Sales0.00M P/S- EPS this Y3.54% Inst Trans1.29% Short Ratio5.59 Perf Half Y27.81%
Book/sh11.14 P/B3.95 EPS next Y-6.34% ROA-36.44% Short Interest5.03M Perf Year116.74%
Cash/sh11.42 P/C3.85 EPS next 5Y- ROE-40.76% 52W Range15.76 - 53.70 Perf YTD23.78%
Dividend Est.- P/FCF- EPS past 5Y-10.59% ROI-25.55% 52W High-17.98% Beta0.68
Dividend TTM- Quick Ratio17.72 Sales past 5Y64.83% Gross Margin-105.50% 52W Low179.46% ATR (14)1.93
Dividend Ex-Date- Current Ratio17.72 EPS Y/Y TTM-15.15% Oper. Margin0.00% RSI (14)41.71 Volatility3.69% 4.27%
Employees290 Debt/Eq0.06 Sales Y/Y TTM-100.00% Profit Margin- Recom1.21 Target Price66.43
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q-8.52% Payout- Rel Volume0.57 Prev Close44.71
Sales Surprise220.00% EPS Surprise-14.87% Sales Q/Q- EarningsMay 09 AMC Avg Volume899.25K Price44.04
SMA20-5.81% SMA50-5.08% SMA20018.92% Trades Volume125,648 Change-1.49%
Date Action Analyst Rating Change Price Target Change
Mar-06-24Initiated Citigroup Buy $68
Jan-16-24Initiated Morgan Stanley Overweight $50
Dec-21-23Initiated Jefferies Hold $35
Nov-20-23Resumed JP Morgan Overweight $35
Oct-24-23Resumed Cantor Fitzgerald Overweight $52 → $50
Aug-31-23Initiated Oppenheimer Outperform $40
Apr-24-23Initiated Piper Sandler Overweight $56
Mar-30-23Initiated Robert W. Baird Outperform $48
Nov-30-21Initiated JMP Securities Mkt Outperform $43
Nov-23-21Initiated Evercore ISI Outperform $68
Jun-12-24 02:38AM
Jun-10-24 06:35PM
Jun-03-24 12:16PM
12:00PM
12:00PM
02:46AM Loading…
May-31-24 02:46AM
May-30-24 04:05PM
May-22-24 08:00AM
May-16-24 05:23PM
May-13-24 10:53AM
May-10-24 05:38PM
05:03PM
12:47PM
May-09-24 08:55PM
05:35PM
05:03PM Loading…
05:03PM
04:05PM
May-08-24 04:05PM
May-07-24 08:55AM
May-02-24 04:05PM
Apr-11-24 04:05PM
Mar-28-24 08:10AM
Mar-26-24 07:01PM
Mar-22-24 07:02PM
07:02PM
Mar-21-24 02:32AM
Mar-20-24 11:46AM
05:14AM
Mar-19-24 04:48PM
04:03PM
08:08AM Loading…
08:08AM
06:16AM
06:08AM
06:00AM
Mar-12-24 04:05PM
Mar-11-24 04:05PM
Mar-01-24 08:57AM
Feb-28-24 04:36PM
04:05PM
08:00AM
Feb-15-24 03:14AM
Feb-14-24 04:05PM
Feb-12-24 04:05PM
Jan-26-24 11:01PM
Jan-13-24 05:03AM
Jan-10-24 04:33PM
Jan-05-24 03:03AM
Jan-03-24 08:00AM
Dec-29-23 07:02AM
Dec-23-23 05:01AM
Dec-18-23 04:05PM
Dec-11-23 04:05PM
Dec-03-23 05:25AM
Nov-20-23 04:05PM
Nov-17-23 08:39AM
Nov-10-23 05:00PM
Nov-09-23 05:45AM
Nov-08-23 09:55AM
08:50AM
Nov-07-23 04:05PM
Nov-04-23 05:03AM
Oct-23-23 09:55AM
08:50AM
Oct-20-23 01:02AM
Oct-11-23 09:00AM
Oct-10-23 05:00PM
Oct-03-23 07:00AM
Sep-28-23 11:18AM
Sep-20-23 08:00AM
Sep-15-23 08:37AM
Sep-12-23 10:26PM
Sep-11-23 04:04PM
04:01PM
12:57PM
06:00AM
05:43AM
Sep-10-23 10:00AM
Sep-05-23 08:55PM
Aug-13-23 09:02AM
Aug-10-23 05:34PM
Aug-08-23 07:00AM
Jul-31-23 08:01AM
Jul-10-23 04:18PM
Jun-21-23 07:59AM
Jun-12-23 07:30AM
Jun-09-23 07:30AM
May-10-23 04:21PM
May-06-23 08:07AM
May-04-23 07:35PM
04:05PM
10:00AM
Apr-16-23 09:34AM
Apr-10-23 04:31PM
Mar-28-23 03:57PM
Mar-10-23 04:37PM
Mar-06-23 07:05AM
Feb-28-23 05:25PM
04:05PM
Feb-10-23 05:21PM
08:01AM
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Betz Stephen F.Chief Scientific OfficerJun 10 '24Sale43.863,000131,58083,643Jun 11 04:35 PM
Betz Stephen F.Chief Scientific OfficerMay 28 '24Sale47.493,000142,47086,643May 30 04:28 PM
Betz Stephen F.Chief Scientific OfficerMay 10 '24Sale49.433,000148,29089,643May 14 06:29 PM
Struthers Richard ScottPresident & CEOMay 08 '24Option Exercise9.28107,448997,117364,933May 10 04:57 PM
Struthers Richard ScottPresident & CEOMay 08 '24Sale49.40107,4485,307,931257,485May 10 04:57 PM
Pizzuti DanaChief Med and Dev OfficerApr 15 '24Option Exercise16.8914,375242,79442,161Apr 17 04:36 PM
Struthers Richard ScottPresident & CEOApr 15 '24Option Exercise1.9120,00038,200257,835Apr 17 04:30 PM
Pizzuti DanaChief Med and Dev OfficerApr 15 '24Sale44.4714,375639,25627,786Apr 17 04:36 PM
Struthers Richard ScottPresident & CEOApr 04 '24Option Exercise9.2840,951380,025278,786Apr 08 05:09 PM
Struthers Richard ScottPresident & CEOApr 04 '24Sale49.1740,9512,013,561237,835Apr 08 05:09 PM
Okey StephanieDirectorMar 28 '24Option Exercise18.2917,500320,07523,500Apr 02 04:35 PM
Okey StephanieDirectorMar 28 '24Sale46.3817,500811,6506,000Apr 02 04:35 PM
Knight Jeff E.Chief Operating OfficerMar 22 '24Option Exercise23.9830,000719,40084,939Mar 26 04:30 PM
Knight Jeff E.Chief Operating OfficerMar 22 '24Sale44.3132,3591,433,67552,580Mar 26 04:30 PM
Fust Matthew KDirectorMar 20 '24Option Exercise20.9260,0001,254,97536,036Mar 22 04:31 PM
Pizzuti DanaChief Med and Dev OfficerMar 20 '24Option Exercise16.8914,375242,79438,500Mar 22 04:52 PM
Fust Matthew KDirectorMar 20 '24Sale44.1460,0002,648,15018,536Mar 22 04:31 PM
Pizzuti DanaChief Med and Dev OfficerMar 20 '24Sale44.0615,089664,76327,786Mar 22 04:52 PM
Wilson MarcCFOMar 19 '24Sale42.916,942297,881110,630Mar 20 06:32 PM
Betz Stephen F.Chief Scientific OfficerJan 25 '24Sale37.263,000111,78073,298Jan 26 05:50 PM
Betz Stephen F.Chief Scientific OfficerJan 10 '24Sale37.653,000112,95076,298Jan 12 04:12 PM
Pizzuti DanaChief Med and Dev OfficerJan 03 '24Option Exercise16.8914,375242,79420,286Jan 04 04:45 PM
Pizzuti DanaChief Med and Dev OfficerJan 03 '24Sale35.0014,375503,1255,911Jan 04 04:45 PM
Wilson MarcCFOJan 02 '24Option Exercise9.2810,00092,800106,055Jan 04 04:43 PM
Wilson MarcCFOJan 02 '24Sale35.4710,000354,70096,055Jan 04 04:43 PM
Betz Stephen F.Chief Scientific OfficerDec 26 '23Sale35.893,000107,67079,298Dec 27 05:20 PM
Pizzuti DanaChief Med and Dev OfficerDec 21 '23Option Exercise16.899,583161,85715,494Dec 22 06:45 PM
Pizzuti DanaChief Med and Dev OfficerDec 21 '23Sale34.579,583331,2845,911Dec 22 06:45 PM
Betz Stephen F.Chief Scientific OfficerDec 11 '23Sale32.873,00098,61082,298Dec 13 04:44 PM
Betz Stephen F.Chief Scientific OfficerNov 27 '23Sale31.843,00095,52085,298Nov 29 04:31 PM
Struthers Richard ScottPresident & CEONov 09 '23Option Exercise1.9150,00095,500185,522Nov 13 04:33 PM
Struthers Richard ScottPresident & CEONov 03 '23Option Exercise9.28199,0821,847,481334,604Nov 06 06:02 PM
Struthers Richard ScottPresident & CEONov 03 '23Sale30.56199,0826,083,946135,522Nov 06 06:02 PM
Struthers Richard ScottPresident & CEONov 02 '23Option Exercise9.289188,519136,440Nov 06 06:02 PM
Struthers Richard ScottPresident & CEONov 02 '23Sale29.9591827,494135,522Nov 06 06:02 PM
Wilson MarcCFONov 01 '23Option Exercise9.2810,00092,800105,601Nov 03 07:38 PM
Wilson MarcCFONov 01 '23Sale28.7510,000287,50095,601Nov 03 07:38 PM
Krasner Alan SethChief Medical OfficerOct 17 '23Option Exercise12.017,00084,07050,210Oct 19 05:01 PM
Krasner Alan SethChief Medical OfficerOct 17 '23Sale30.007,000210,00043,210Oct 19 05:01 PM
Struthers Richard ScottPresident & CEOAug 14 '23Option Exercise1.9110,00019,100135,522Aug 16 04:30 PM
Struthers Richard ScottPresident & CEOJul 13 '23Sale20.3514,157288,095630,805Jul 13 04:56 PM
Struthers Richard ScottPresident & CEOJul 12 '23Sale20.1711,459231,128644,962Jul 13 04:56 PM
Struthers Richard ScottPresident & CEOJul 11 '23Sale20.1424,384491,094656,421Jul 13 04:56 PM
Wilson MarcCFOJun 20 '23Option Exercise9.2820,000185,600115,158Jun 21 05:32 PM
Wilson MarcCFOJun 20 '23Sale19.9730,922617,40395,158Jun 21 05:32 PM